SYN-114 and SYN-120 are both orally bioavailable potent and selective antagonists of the 5-HT6 receptor. The 5-HT6 receptors are exclusively located in the brain and antagonism of the receptor modulates the release of acetylcholine and glutamate, two neurotransmitters known to be involved with memory function. Cognitive deficits are an important component of many CNS diseases especially Alzheimer’s and schizophrenia. SYN-114 has completed a Phase I single ascending dose and multiple ascending dose studies, and SYN-120 has completed a single ascending dose study. Synosia plans to initiate a multiple ascending dose-study for SYN-120 in Q2 2010.
This programme is partnered with Roche and Roche has a buy-back right at a pre-specified milestone.